Ashley Gallagher, MA

Georgia Travlos, PharmD, discusses changes in influenza and respiratory syncytial virus immunizations and coadministration best practices.

A study reveals that lower baseline BMI and early weight loss with liraglutide enhance significant weight loss outcomes in patients with type 2 diabetes.

Patients and physicians favor at-home remdesivir treatment for COVID-19, highlighting satisfaction and confidence in telehealth and nursing support.

PCV21 improved all outcomes for individuals aged 19 to 64 years, including invasive pneumococcal disease, postmeningitis sequelae, and nonbacteremic pneumococcal pneumonia.

Research reveals no significant disparities in cardiovascular disease incidence linked to mental disorders after the COVID-19 pandemic.

Pharmacies evolve with flexible designs and enhanced roles for pharmacists, improving patient care and privacy in community health settings.

Investigators explore how long COVID impacts trust in vaccines, revealing diverse patient experiences and the need for better communication in public health.

Pharmacists can help patients navigate the vast array of OTC options for effective pain relief, fever reduction, and targeted symptom management.

Tezspire gains FDA approval as the first biologic for chronic rhinosinusitis with nasal polyps, offering improved patient outcomes.

Pharmacists enhance patient care through automation, blood pressure monitoring, and community health services, improving accessibility and reducing burnout.

FDA approves oral semaglutide for reducing cardiovascular risks in high-risk type 2 diabetes patients, enhancing treatment options and outcomes.

A recent study reveals a heightened stroke risk in asthma patients recovering from severe COVID-19, emphasizing the need for proactive monitoring and management.

The FDA expands Yuflyma's approval to treat hidradenitis suppurativa and uveitis in pediatric patients, enhancing treatment options for chronic conditions.

Orforglipron demonstrates superior glycemic control in phase 3 trials, showing promise as a new treatment for type 2 diabetes.

The FDA approves the Insti HIV Self Test, enabling rapid, accurate results in just one minute, enhancing access to HIV testing nationwide.

A study shows young adults with 3 or more COVID-19 vaccine doses experience fewer symptoms, emphasizing vaccination's critical role in public health.

As misinformation persists, health experts and research point to pharmacists as key communicators in building trust and boosting immunization rates.

CVS Pharmacy acquires Rite Aid assets in the Pacific Northwest, enhancing pharmacy access while addressing the growing crisis of pharmacy closures nationwide.

The biosimilar is also approved for indications of Eylea, including neovascular age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic retinopathy.

The FDA approves Uzedy, a long-acting risperidone injection, enhancing treatment options for adults with bipolar I disorder and addressing unmet needs.

Pharmacists navigate financial challenges and evolving roles, requiring communication and problem-solving skills amid technological advancements.

David Nau, BSPH, PhD, discusses evolving landscape of pharmacy, highlighting resilience, innovation, and new opportunities for future pharmacists in a changing health care world.

Pharmacists evolve by enhancing skills, embracing AI, and focusing on patient care, ensuring relevance in a changing health care landscape.

Further, they found weight loss prior to 75-g oral glucose tolerance test was a preventive factor for both impaired glucose tolerance and diabetes.

Amgen launches AmgenNow, which is a new direct-to-patient program that will start with evolucumab.

Don Roosan, PharmD, PhD, discusses the ethical implications of AI in pharmacy, focusing on patient safety, transparency, and the importance of human connection in care.

Don Roosan, PharmD, PhD, discusses the changing technology, challenging conventional boundaries of pharmaceutical practice through telepharmacy and artificial intelligence.

Prior to the government shutdown, the FDA approved a generic version of mifeprisone without a public announcement.

This is the first Bruton tyrosine kinase inhibitor FDA approved for chronic spontaneous urticaria.

This month, Drug Topics® explores a new avenue of pharmacy each week, including AI technology, student education, innovative community services, and the expansion of clinical care.